Cannabinoids Effect on Central and Peripheral Pain Modulation in Fibromyalgia
Fibromyalgia, Primary
About this trial
This is an interventional treatment trial for Fibromyalgia, Primary
Eligibility Criteria
Inclusion Criteria: Diagnosed with fibromyalgia for over 3 months according to American college of rheumatology Do not respond well to analgesic medications and or have severe side effects Medium to high level of pain (over 40 on visual analogue scale scale) Does not have other pain-related syndromes Not treated regularly with cannabis. Is ready to stop taking central nervous system medications 3 days prior to the experiment. Exclusion Criteria: alleviated levels of anxiety (above 52 in STAI) Psychiatric medications due to psychiatric diagnoses (depression, bi-polar syndrome, etc.). Cardiovascular problems Neurological diseases (other than migraine). Pregnancy or breastfeeding Alcoholism or substance abuse Cancer Blood pressure problems Patients that used cannabis in the past month Illegibility to MRI
Sites / Locations
- Tel Aviv Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Treatment (THC)
Placebo
patients will receive a single dose of 0.15 mg/kg cannabis oil T10/C2 (AXIBAN).
Placebo control